CRLX101: Phase I data

Data from 24 patients in the Phase I portion of an ongoing, open-label, U.S. Phase I/IIa trial showed that IV CRLX101 given every other week was well tolerated and produced 4 cases of stable disease for >6 months. Data were presented at the American Chemical Society meeting in Boston. ...